Connor, Clark & Lunn Investment Management (CC&L)’s Sage Therapeutics SAGE Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-187,048	Closed	-$1.49M	–	1665
2025 Q1	$1.49M	Buy	187,048 +17,991	+11%	+$132K	0.01%	814
2024 Q4	$918K	Buy	169,057 +103,495	+158%	+$633K	﹤0.01%	965
2024 Q3	$473K	Buy	+65,562	New	+$600K	﹤0.01%	1112
2023 Q3	–	Sell	-93,329	Closed	-$4.39M	–	1518
2023 Q2	$4.39M	Sell	93,329 -15,293	-14%	-$761K	0.02%	426
2023 Q1	$4.56M	Sell	108,622 -7,043	-6%	-$303K	0.02%	388
2022 Q4	$4.41M	Buy	115,665 +56,482	+95%	+$2.16M	0.03%	380
2022 Q3	$2.32M	Buy	59,183 +5,540	+10%	+$214K	0.02%	467
2022 Q2	$1.73M	Buy	53,643 +11,140	+26%	+$373K	0.01%	499
2022 Q1	$1.41M	Sell	42,503 -30,874	-42%	-$1.16M	0.01%	591
2021 Q4	$3.12M	Buy	73,377 +19,544	+36%	+$818K	0.02%	432
2021 Q3	$2.38M	Buy	+53,833	New	+$2.47M	0.01%	489
2021 Q2	–	Sell	-10,596	Closed	-$793K	–	1088
2021 Q1	$793K	Buy	10,596 +5,904	+126%	+$484K	﹤0.01%	727
2020 Q4	$406K	Buy	+4,692	New	+$346K	﹤0.01%	749